SCHEMBL1052832

SCHEMBL1052832

OC[C@H]1SC[C@H](O)[C@@H]1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14747279 1.00
SCHEMBL14747638 1.00
SCHEMBL15684458 1.00
SCHEMBL13654911 1.00
SCHEMBL984959 1.00
SCHEMBL6101587 1.00
SCHEMBL13841808 1.00
SCHEMBL29571910 0.92 GAA (0.36)
SCHEMBL5126049 0.92 GAA (0.36)
SCHEMBL19764396 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353838-A1 METHOD FOR PREPARING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE PINOTBIO, INC. (KR) 2025-11-20 US disclosed
EP-4524145-A1 METHOD FOR PREPARING 4?-THIO-5-AZA-2?-DEOXYCYTIDINE Pinotbio, Inc. (KR) 2025-03-19 EP disclosed
EP-3833668-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2025-03-19 EP disclosed
US-11993602-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2024-05-28 US disclosed
CN-117460736-A Nucleoside derivatives having multi-target phosphorylase inhibitory activity and pharmaceutical compositions for preventing and treating cancer comprising the same 未来制药有限公司 2024-01-26 CN disclosed
WO-2023239190-A1 METHOD FOR PREPARING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE 주식회사 피노바이오 2023-12-14 WO disclosed
WO-2023239190-A1 METHOD FOR PREPARING 4'-THIO-5-AZA-2'-DEOXYCYTIDINE 주식회사 피노바이오 2023-12-14 WO disclosed
US-20230192753-A1 RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS RANA THERAPEUTICS, INC. 2023-06-22 US disclosed
US-20230192753-A1 RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS RANA THERAPEUTICS, INC. 2023-06-22 US disclosed
US-20210277009-A1 PRMT5 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2021-09-09 US disclosed
US-20100324277-A1 OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2010-12-23 US disclosed
US-20100324277-A1 OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2010-12-23 US disclosed
US-20100324277-A1 OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2010-12-23 US disclosed
EP-1677822-A4 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS INC (US) 2009-08-19 EP disclosed
WO-2007098597-A1 GLYCOSIDASE INHIBITORS AND METHODS OF SYNTHESIZING SAME SIMON FRASER UNIVERSITY (CA) 2007-09-07 WO disclosed
US-20060247222-A1 Glycosidase inhibitors and methods of synthesizing same SIMON FRASER UNIVERSITY (CA) 2006-11-02 US disclosed
WO-2005027962-A9 4’-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS INC (US) 2006-08-10 WO disclosed
EP-1677822-A2 4'-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2006-07-12 EP disclosed
US-20050130923-A1 Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing IONIS PHARMACEUTICALS, INC. 2005-06-16 US disclosed
WO-2005027962-A1 4’-THIONUCLEOSIDES AND OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed